Nuedexta

RSS

Withdrawn

This medicine's authorisation has been withdrawn

dextromethorphan hydrobromide / quinidine sulfate
MedicineHumanWithdrawn

French is available via eTranslation, the European Commission's machine translation service.

Translate to French | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 15 February 2016 the European Commission withdrew the marketing authorisation for Nuedexta (dextromethorphan / quinidine) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Jenson Pharmaceutical Services Ltd, which notified the European Commission of its decision not to market the product in the EU for commercial reasons. 

Nuedexta was granted marketing authorisation in the EU on 24 June 2013 for treatment of pseudobulbar affect (PBA) in adults. The product had not been marketed in the EU. 

The European Public Assessment Report (EPAR) for Nuedexta is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

български (BG) (312.89 Ko - PDF)

Voir

español (ES) (266.25 Ko - PDF)

Voir

čeština (CS) (293.48 Ko - PDF)

Voir

dansk (DA) (266.6 Ko - PDF)

Voir

Deutsch (DE) (267.83 Ko - PDF)

Voir

eesti (ET) (269.56 Ko - PDF)

Voir

ελληνικά (EL) (320.31 Ko - PDF)

Voir

français (FR) (267.84 Ko - PDF)

Voir

hrvatski (HR) (283.73 Ko - PDF)

Voir

italiano (IT) (264.25 Ko - PDF)

Voir

latviešu (LV) (302.74 Ko - PDF)

Voir

lietuvių (LT) (283 Ko - PDF)

Voir

magyar (HU) (284.97 Ko - PDF)

Voir

Malti (MT) (290.76 Ko - PDF)

Voir

Nederlands (NL) (264.69 Ko - PDF)

Voir

polski (PL) (284.4 Ko - PDF)

Voir

português (PT) (286.28 Ko - PDF)

Voir

română (RO) (268.86 Ko - PDF)

Voir

slovenčina (SK) (285.42 Ko - PDF)

Voir

slovenščina (SL) (286.75 Ko - PDF)

Voir

suomi (FI) (262.95 Ko - PDF)

Voir

svenska (SV) (265.02 Ko - PDF)

Voir

Product information

български (BG) (1.24 Mo - PDF)

Voir

español (ES) (638.47 Ko - PDF)

Voir

čeština (CS) (994 Ko - PDF)

Voir

dansk (DA) (630.24 Ko - PDF)

Voir

Deutsch (DE) (690.2 Ko - PDF)

Voir

eesti (ET) (627.09 Ko - PDF)

Voir

ελληνικά (EL) (1.36 Mo - PDF)

Voir

français (FR) (691.37 Ko - PDF)

Voir

hrvatski (HR) (642.16 Ko - PDF)

Voir

italiano (IT) (651.76 Ko - PDF)

Voir

latviešu (LV) (994.32 Ko - PDF)

Voir

lietuvių (LT) (810.7 Ko - PDF)

Voir

magyar (HU) (994.57 Ko - PDF)

Voir

Malti (MT) (1.04 Mo - PDF)

Voir

Nederlands (NL) (663.87 Ko - PDF)

Voir

polski (PL) (1.71 Mo - PDF)

Voir

português (PT) (649.06 Ko - PDF)

Voir

română (RO) (655.52 Ko - PDF)

Voir

slovenčina (SK) (976.88 Ko - PDF)

Voir

slovenščina (SL) (925.24 Ko - PDF)

Voir

suomi (FI) (653.71 Ko - PDF)

Voir

svenska (SV) (642.3 Ko - PDF)

Voir

Íslenska (IS) (955.72 Ko - PDF)

Voir

norsk (NO) (943.33 Ko - PDF)

Voir
Latest procedure affecting product information:IAIN/0005
24/10/2014
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (167.05 Ko - PDF)

Voir

español (ES) (153.71 Ko - PDF)

Voir

čeština (CS) (160.1 Ko - PDF)

Voir

dansk (DA) (154.47 Ko - PDF)

Voir

Deutsch (DE) (154.57 Ko - PDF)

Voir

eesti (ET) (153.66 Ko - PDF)

Voir

ελληνικά (EL) (177.22 Ko - PDF)

Voir

français (FR) (153.69 Ko - PDF)

Voir

hrvatski (HR) (282.98 Ko - PDF)

Voir

italiano (IT) (152.66 Ko - PDF)

Voir

latviešu (LV) (164.45 Ko - PDF)

Voir

lietuvių (LT) (154.89 Ko - PDF)

Voir

magyar (HU) (160.64 Ko - PDF)

Voir

Malti (MT) (160.78 Ko - PDF)

Voir

Nederlands (NL) (153.75 Ko - PDF)

Voir

polski (PL) (159.71 Ko - PDF)

Voir

português (PT) (154.08 Ko - PDF)

Voir

română (RO) (153.69 Ko - PDF)

Voir

slovenčina (SK) (159.39 Ko - PDF)

Voir

slovenščina (SL) (157.93 Ko - PDF)

Voir

suomi (FI) (152.94 Ko - PDF)

Voir

svenska (SV) (136.89 Ko - PDF)

Voir

Íslenska (IS) (169.64 Ko - PDF)

Voir

norsk (NO) (170.1 Ko - PDF)

Voir

Product details

Name of medicine
Nuedexta
Active substance
  • dextromethorphan
  • quinidine
International non-proprietary name (INN) or common name
  • dextromethorphan hydrobromide
  • quinidine sulfate
Therapeutic area (MeSH)
Neurobehavioral Manifestations
Anatomical therapeutic chemical (ATC) code
N07XX59

Pharmacotherapeutic group

Other nervous system drugs

Therapeutic indication

Nuedexta is indicated for the symptomatic treatment of pseudobulbar affect (PBA) in adults. Efficacy has only been studied in patients with underlying amyotrophic lateral sclerosis or multiple sclerosis.

Authorisation details

EMA product number
EMEA/H/C/002560
Marketing authorisation holder
Jenson Pharmaceutical Services Limited

Carradine House
237 Regents Park Road
London
N3 3LF
United Kingdom

Marketing authorisation issued
24/06/2013
Withdrawal of marketing authorisation
15/02/2016
Revision
2

Assessment history

This page was last updated on

Share this page